Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis

被引：8
作者：
Bourdette, Dennis [1 ,2 ]
Hartung, Daniel [3 ]
机构：
[1] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA
[2] Vet Affairs Portland Hlth Care Syst, Multiple Sclerosis Ctr Excellence West, Portland, OR USA
[3] Oregon Hlth & Sci Univ, Oregon State Univ, Coll Pharm, Portland, OR 97201 USA
来源：
JAMA NEUROLOGY | 2015年 / 72卷 / 12期
关键词：
TRIAL; MULTICENTER; COPAXONE(R); COP-1; DRUGS;
D O I：
10.1001/jamaneurol.2015.2605
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1411 / 1413
页数：4
相关论文
共 50 条
  • [31] Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis A Randomized Clinical Trial
    Cree, Bruce A. C.
    Goldman, Myla D.
    Corboy, John R.
    Singer, Barry A.
    Fox, Edward J.
    Arnold, Douglas L.
    Ford, Corey
    Weinstock-Guttman, Bianca
    Bar-Or, Amit
    Mientus, Susanne
    Sienkiewicz, Daniel
    Zhang, Ying
    Karan, Rajesh
    Tenenbaum, Nadia
    JAMA NEUROLOGY, 2021, 78 (01) : 48 - 60
  • [32] Benefit-Risk Analysis of Glatiramer Acetate for Relapsing-Remitting and Clinically Isolated Syndrome Multiple Sclerosis
    Qizilbash, Nawab
    Mendez, Ignacio
    Sanchez-de la Rosa, Rainel
    CLINICAL THERAPEUTICS, 2012, 34 (01) : 159 - 176
  • [33] Equivalence of glatiramer acetate products: challenges in assessing pharmaceutical equivalence and critical clinical performance attributes
    Borchard, G.
    Crommelin, D. J. A.
    EXPERT OPINION ON DRUG DELIVERY, 2018, 15 (03) : 247 - 259
  • [34] Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis
    Schipper, Hyman M.
    Arnold, Douglas
    Grand'Maison, Francois
    Melmed, Calvin
    Moore, Fraser
    Levental, Mark
    Su, Haixiang
    Constantin, Michel
    Stril, Jean-Louis
    Godin, Jean
    CLINICAL NEUROPHARMACOLOGY, 2015, 38 (04) : 127 - 131
  • [35] Glatiramer acetate: A complex drug beyond biologics
    Rocco, Paolo
    Eberini, Ivano
    Musazzi, Umberto M.
    Franze, Silvia
    Minghetti, Paola
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 133 : 8 - 14
  • [36] Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results
    Selmaj, Krzysztof
    Barkhof, Frederik
    Belova, Anna N.
    Wolf, Christian
    van den Tweel, Evelyn R. W.
    Oberye, Janine J. L.
    Mulder, Roel
    Egging, David F.
    Koper, Norbert P.
    Cohen, Jeffrey A.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (14) : 1909 - 1917
  • [37] Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a
    Bovis, Francesca
    Kalincik, Tomas
    Lublin, Fred
    Cutter, Gary
    Malpas, Charles
    Horakova, Dana
    Havrdova, Eva Kubala
    Trojano, Maria
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Onofrj, Marco
    Lugaresi, Alessandra
    Izquierdo, Guillermo
    Eichau, Sara
    Patti, Francesco
    Terzi, Murat
    Grammond, Pierre
    Bergamaschi, Roberto
    Sola, Patrizia
    Ferraro, Diana
    Ozakbas, Serkan
    Iuliano, Gerardo
    Boz, Cavit
    Hupperts, Raymond
    Grand'Maison, Francois
    Oreja-Guevara, Celia
    van Pesch, Vincent
    Cartechini, Elisabetta
    Petersen, Thor
    Altintas, Ayse
    Soysal, Aysun
    Ramo-Tello, Cristina
    McCombe, Pamela
    Turkoglu, Recai
    Butzkueven, Helmut
    Wolinsky, Jerry S.
    Solaro, Claudio
    Sormani, Maria Pia
    NEUROLOGY, 2021, 96 (02) : E214 - E227
  • [38] Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study
    Zivadinov, Robert
    Bergsland, Niels
    Hagemeier, Jesper
    Tavazzi, Eleonora
    Ramasamy, Deepa P.
    Durfee, Jackie
    Cherneva, Mariya
    Carl, Ellen
    Carl, Jillian
    Kolb, Channa
    Hojnacki, David
    Weinstock-Guttman, Bianca
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2018, 387 : 152 - 156
  • [39] Glatiramer Acetate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis and in Delaying the Onset of Clinically Definite Multiple Sclerosis
    Scott, Lesley J.
    CNS DRUGS, 2013, 27 (11) : 971 - 988
  • [40] Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
    Honce, Justin M.
    Nair, Kavita, V
    Hoyt, Brian D.
    Seale, Rebecca A.
    Sillau, Stefan
    Engebretson, Eric
    Schurr, Brittany
    Corboy, John R.
    Vollmer, Timothy L.
    Alvarez, Enrique
    FRONTIERS IN NEUROLOGY, 2020, 11
12345